Targeted delivery of bioactive molecules to diseased organs or tissues by means of binding molecules specific to markers of diseases represents a promising area of pharmaceutical intervention. The availability of markers of pathology, ideally accessible from the vasculature, is crucial for such strategies. To this aim, here we present a protocol based on terminal perfusion of mice with a reactive ester derivate of biotin that enables the covalent modification of proteins readily accessible from the bloodstream. Biotinylated proteins from total organ or tissue extracts are (i) purified on streptavidin resin in the presence of strong detergents, (ii) digested on the resin and (iii) subjected to proteomic analysis. This technology is applicable to comparative proteomic investigations of differentially expressed, accessible proteins in numerous animal models having different physiological and pathological processes.
Subscribe to Journal
Get full journal access for 1 year
only $41.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Neri, D. & Bicknell, R. Tumour vascular targeting. Nat. Rev. Cancer 5, 436–446 (2005).
Huang, X. et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275, 547–550 (1997).
Wu, A.M. & Senter, P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137–1146 (2005).
Adams, G.P. & Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147–1157 (2005).
Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118–129 (2001).
Winter, G., Griffiths, A.D., Hawkins, R.E. & Hoogenboom, H.R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433–455 (1994).
Silacci, M. et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5, 2340–2350 (2005).
Collins, J., Horn, N., Wadenback, J. & Szardenings, M. Cosmix-plexing: a novel recombinatorial approach for evolutionary selection from combinatorial libraries. J. Biotechnol. 74, 317–338 (2001).
Brody, E.N. & Gold, L. Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 74, 5–13 (2000).
Erlanson, D.A. et al. In situ assembly of enzyme inhibitors using extended tethering. Nat. Biotechnol. 21, 308–314 (2003).
Melkko, S., Scheuermann, J., Dumelin, C.E. & Neri, D. Encoded self-assembling chemical libraries. Nat. Biotechnol. 22, 568–574 (2004).
Shuker, S.B., Hajduk, P.J., Meadows, R.P. & Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531–1534 (1996).
St. Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197–1202 (2000).
Huminiecki, L. & Bicknell, R. In silico cloning of novel endothelial-specific genes. Genome Res. 10, 1796–1806 (2000).
Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364–366 (1996).
Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377–380 (1998).
Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429, 629–635 (2004).
Rybak, J.N. et al. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat. Methods 2, 291–298 (2005).
Rybak, J.N., Scheurer, S.B., Neri, D. & Elia, G. Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics 4, 2296–2299 (2004).
Zardi, L. et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6, 2337–2342 (1987).
Pini, A. et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273, 21769–21776 (1998).
Castellani, P. et al. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol. 161, 1695–1700 (2002).
Borsi, L. et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102, 75–85 (2002).
Berndorff, D. et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin. Cancer Res. 11, 7053s–7063s (2005).
Carnemolla, B. et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99, 1659–1665 (2002).
Ebbinghaus, C. et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer 116, 304–313 (2005).
Menrad, A. & Menssen, H.D. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin. Ther. Targets 9, 491–500 (2005).
We are grateful to the Functional Genomics Center Zurich for access to mass spectrometers and support. Financial support from the EU project STROMA, the Bundesamt für Bildung und Wissenschaft (FLUOR-MMPI and STROMA), the Swiss National Science Foundation and the Gebert-Rüf Foundation are gratefully acknowledged.
The authors declare no competing financial interests.
About this article
Cite this article
Roesli, C., Neri, D. & Rybak, J. In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. Nat Protoc 1, 192–199 (2006). https://doi.org/10.1038/nprot.2006.29
Current Opinion in Chemical Biology (2019)
Sphingosine 1-phosphate receptor 1 regulates cell-surface localization of membrane proteins in endothelial cells
Biochimica et Biophysica Acta (BBA) - General Subjects (2019)
Translational and Regulatory Sciences (2019)
Arteriosclerosis, Thrombosis, and Vascular Biology (2018)